Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate
- 1 February 2003
- journal article
- spotlight correspondence
- Published by Springer Nature in Leukemia
- Vol. 17 (2) , 461-463
- https://doi.org/10.1038/sj.leu.2402813
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Cytogenetics of chronic myeloid leukaemiaBest Practice & Research Clinical Haematology, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α TherapyAnnals of Internal Medicine, 1995
- Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemiaBlood, 1988